Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Capital Expenditures (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Capital Expenditures data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 258.97% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.7 million, up 840.54%, while the annual FY2025 figure was $1.7 million, 840.54% up from the prior year.
  • Capital Expenditures reached $1.4 million in Q4 2025 per COLL's latest filing, up from -$549000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.4 million in Q4 2025 and bottomed at -$897000.0 in Q4 2024.
  • Average Capital Expenditures over 5 years is $297600.0, with a median of $226000.0 recorded in 2021.
  • The widest YoY moves for Capital Expenditures: up 1256.92% in 2024, down 757.14% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $515000.0 in 2021, then skyrocketed by 82.52% to $940000.0 in 2022, then crashed by 82.55% to $164000.0 in 2023, then plummeted by 646.95% to -$897000.0 in 2024, then surged by 258.97% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $1.4 million in Q4 2025, -$549000.0 in Q3 2025, and $65000.0 in Q2 2025.